Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -8.21% is 88% above its 5-year average of -70.70%, near the high end of its 5-year range (-179.44%–-1.97%).
As of the fiscal period ended Tuesday, June 30, 2026. 42.27% above its 12-month average of -14.22%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q3 FY2026 (2026-06-30): -8.21%.
RETURN ON EQUITY (ROE)
-8.21%
RETURN ON EQUITY (ROE) AVG TTM
-14.22%
RETURN ON EQUITY (ROE) AVG 3Y
-47.47%
RETURN ON EQUITY (ROE) AVG 5Y
-70.70%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+42.27%
CURRENT VS 3Y AVG
+82.70%
CURRENT VS 5Y AVG
+88.39%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-38.17%
median of 441 covered companies
CURRENT VS SECTOR MEDIAN
+78.49%
vs the sector median at left
Bright Minds Biosciences Inc.
Market Cap
$487.30M
Return on Equity (ROE)
-8.21%
TTM Avg
-14.22%
3Y Avg
-47.47%
5Y Avg
-70.70%
Market Cap
$491.55M
Return on Equity (ROE)
-6.60%
TTM Avg
-10.82%
3Y Avg
-11.36%
5Y Avg
-7.59%
Market Cap
$491.93M
Return on Equity (ROE)
N/A
TTM Avg
-344.79%
3Y Avg
-198.42%
5Y Avg
-104.57%
Market Cap
$481.33M
Return on Equity (ROE)
1.65%
TTM Avg
-27.02%
3Y Avg
-39.92%
5Y Avg
-33.78%
Market Cap
$478.54M
Return on Equity (ROE)
-24.02%
TTM Avg
-22.16%
3Y Avg
-34.88%
5Y Avg
-37.32%
Market Cap
$471.57M
Return on Equity (ROE)
-9.69%
TTM Avg
-30.79%
3Y Avg
-49.02%
5Y Avg
-53.00%
Market Cap
$468.31M
Return on Equity (ROE)
89.43%
TTM Avg
81.07%
3Y Avg
67.39%
5Y Avg
61.90%
Market Cap
$461.55M
Return on Equity (ROE)
8.25%
TTM Avg
6.54%
3Y Avg
3.79%
5Y Avg
3.91%
Market Cap
$517.73M
Return on Equity (ROE)
-37.94%
TTM Avg
-63.13%
3Y Avg
-60.30%
5Y Avg
-47.34%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bright Minds Biosciences Inc. (DRUG) | $487.30M | -8.21% | -14.22% | -47.47% | -70.70% |
| NeoGenomics, Inc. (NEO)vs › | $491.55M | -6.60% | -10.82% | -11.36% | -7.59% |
| Evolus, Inc. (EOLS)vs › | $491.93M | N/A | -344.79% | -198.42% | -104.57% |
| Arvinas, Inc. (ARVN)vs › | $481.33M | 1.65% | -27.02% | -39.92% | -33.78% |
| Contineum Therapeutics, Inc. (CTNM)vs › | $478.54M | -24.02% | -22.16% | -34.88% | -37.32% |
| Cerus Corporation (CERS)vs › | $471.57M | -9.69% | -30.79% | -49.02% | -53.00% |
| NRC Health (NRC)vs › | $468.31M | 89.43% | 81.07% | 67.39% | 61.90% |
| Kamada Ltd. (KMDA)vs › | $461.55M | 8.25% | 6.54% | 3.79% | 3.91% |
| Allogene Therapeutics, Inc. (ALLO)vs › | $517.73M | -37.94% | -63.13% | -60.30% | -47.34% |
| Crescent Biopharma, Inc. (CBIO)vs › | $517.79M | -99.83% | 118.83% | 8.21% | -14.12% |
ROE
-8.2%
ROA
-8.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -8.21% |
| 2026-03-31 | -9.00% |
| 2025-12-31 | -22.06% |
| 2025-09-30 | -14.94% |
| 2025-06-30 | -16.91% |
| 2025-03-31 | -6.25% |
| 2024-12-31 | -1.97% |
| 2024-09-30 | -51.30% |
| 2024-06-30 | -59.45% |
| 2024-03-31 | -93.24% |
| 2023-12-31 | -110.11% |
| 2023-09-30 | -112.50% |
| 2023-06-30 | -111.16% |
| 2023-03-31 | -112.51% |
| 2022-12-31 | -117.58% |
| 2022-09-30 | -152.68% |
| 2022-06-30 | -179.44% |
| 2022-03-31 | -145.77% |
| 2021-12-31 | -86.53% |
| 2021-09-30 | -45.12% |
| 2021-06-30 | -28.00% |
| 2021-03-31 | -10.53% |
| 2020-12-31 | -52.92% |
| 2020-09-30 | -65.83% |
